Please use this identifier to cite or link to this item: http://archive.cmb.ac.lk:8080/xmlui/handle/70130/149
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHoppu, Kalle-
dc.contributor.authorRanganathan, Shilani Sri-
dc.contributor.authorDodoo, Alex N. O.-
dc.date.accessioned2011-10-04T11:11:18Z-
dc.date.available2011-10-04T11:11:18Z-
dc.date.issued2011-
dc.identifier.citationArch Dis Child 2011;96:764–768en_US
dc.identifier.urihttp://archive.cmb.ac.lk:8080/research/handle/70130/149-
dc.description.abstractDiseases causing high mortality in children under 5 years of age in resource limited settings (RLS) could be treated if children in these countries had access to existing medicines. It took 30 years before the WHO Essential Medicines List (EML) considered the issue of medicines for children, with the fi rst EML for children being published in 2007. Recent data indicate that less than half of the key paediatric essential medicines are available in countries of sub-Saharan Africa. Problems include substandard medicines, irrational use of medicines, ineffi ciency and even possible corruption in pharmaceutical management systems. These are global issues which affect RLS most. Clinical trials in developing countries for the benefi t of children are needed but challenging in several ways. In this review, the authors will consider the following areas where progress could improve paediatric pharmacotherapy in RLS: registration and regulation of medicines, rational use of medicines, clinical trials in children and restriction of corruption in pharmaceutical management systems.en_US
dc.language.isoenen_US
dc.titleRealities of paediatric pharmacotherapy in the developing worlden_US
dc.typeResearch abstracten_US
Appears in Collections:Department of Pharmacology

Files in This Item:
File Description SizeFormat 
abs.txt1.08 kBTextView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.